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of recurrent aphthous ulcerations and
Kaposi sarcoma in HIV patients with
severe immunosuppressionKishore Shetty *University of Texas Health Sciences Center, Medically Complex Patient Clinic,
6516 M.D. Anderson Blvd., Suite 475, Houston, TX 77030, United StatesReceived 15 August 2005; accepted 16 August 2005Summary Thalidomide is a complex immunomodulatory and antiangiogenic agent
whose role in oncology practice is as yet not fully clear. We present an unusual case
documenting the use of thalidomide in the concurrent management of recurrent
aphthous ulceration and kaposi sarcoma in a patient with severe immmunosuppres-
sion.c 2005 Elsevier Ltd. All rights reserved.
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dIntroduction
A 37 year old African-American presented to the
medically complex patient clinic with recurrence
of an oral ulceration on the right lateral border of
his tongue (Fig. 1). Patient stated he was experi-
encing difficulty swallowing foods secondary to
pain for the past month and had lost 15 pounds.
His medical history was significant for human
immunodeficiency virus, hepatitis B and chronic
depression. Human immunodeficiency virus was
diagnosed in 2000. He had a CD4 count of 145 with741-9409/$ - see front matter c 2005 Elsevier Ltd. All rights reser
oi:10.1016/j.ooe.2005.08.005
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E-mail addresses: orasmile@gmail.com, shettyk@yahoo.coma viral load of 82,000. The patient had a history of
recurrent aphthous ulceration and had been previ-
ously treated with intralesional injections of triam-
cinalone (5 mg/ml) combined with oral prednisone
with limited success. The patient was not on any
antiretroviral therapy and had stopped taking
medication for the past two years against medical
advice. A physical examination revealed mild bilat-
eral cervical lymphadenopathy, no salivary gland
enlargement, no thyromegaly, no conjunctivitis.
Diffuse, reddish-blue, soft, macular lesions on the
posterior left hard palate were observed, with ill-
defined margins extending to and involving the soft
palate (Fig. 2). There was no tenderness. Two
other dark-red nodules were observed on his leftved.
Figure 1 2.5 · 1 cm ill-defined non-indurated ulcerative lesion on the right lateral border of the tongue.
Figure 2 Generalized, diffuse, reddish-blue, soft, macular lesions on the posterior left palate with ill-defined
margins extending to the soft palate. (For interpretation of the references in colour in this figure legend, the reader is
referred to the web version of this article.)
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the oral lesions (Fig. 3). Patient did mention that
he was diagnosed with Kaposi’s sarcoma a few
years ago and was not concerned about the same.
He did not report any eye, nasal, genital or rectal
lesions.
The viral and fungal cultures for the oral lesion
were negative and an incisional biopsy of the ulcer
on the lateral border of tongue was consistent with
major aphthous ulcer (Fig. 4).The punch biopsy of
the palatal lesion was signed out as an endothelial
cell lesion consistent with Kaposi’ sarcoma. Addi-
tionally, head and neck magnetic resonance imag-
ing (MRI) with contrast solution were ordered for
further assessment of respiratory and/or esopha-geal tract obstruction and did not show any major
obstruction of upper airways.
The patient wanted to seek immediate interven-
tion for the ulcerative lesion on the tongue. Given
the failure of traditional therapies, a trial of thalid-
omide for four weeks was initiated. Patient was
started on 200 mg of thalidomide once a day
for four weeks. The patient reported significant
improvement in his symptoms and had no adverse
effect due to the drug. The patient reported
improvement in his symptoms with an 80% resolu-
tion of the lesion after four weeks of therapy.
Thalidomide therapy was continued for four addi-
tional weeks, which resulted in a nearly complete
resolution of the lesions (Fig. 5).
Figure 3 A dark-red macular lesion on the left hand. (For interpretation of the references in colour in this figure
legend, the reader is referred to the web version of this article.)
Figure 4 A medium power resolution of an H&E Stain showing a non-specific ulceration.
Figure 5 Significant improvement and resolution of the apthous ulceration eight weeks after institution of
thalidomide.
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Figure 6 The lesions have decreased in size eight weeks after the initiation of thalidomide therapy.
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tion and shrinkage of the Kaposi sarcoma lesions on
his palate (Fig. 6). The patient had refused to start
antiretroviral therapy during the eight week course
of thalidomide.Discussion
Thalidomide was first marketed in Germany under
the trade name ‘‘Contergan’’ in 1956 then in
England in 1958 under the name of ‘‘Distaval’’.
With few apparent side effects and little toxicity
in animal studies, thalidomide was subsequently
marketed in a number of other countries. In
1960, reports of peripheral neuropathy with
chronic use began to surface. Growing evidence
of severe infant limb defects (phocomelia) and
internal organ deformities associated with mater-
nal use of thalidomide soon eclipsed this lesser
concern. However, in 1961, McBride had noted an
association between thalidomide use by pregnant
women and congenital abnormalities.1 It was esti-
mated that while thalidomide was available,
5000–6000 cases of fetal deformities occurred,
with 4000 of these in Germany which were tempo-
rally related to thalidomide sales. Thalidomide was
withdrawn from the European markets in 1961,
while it was pending approval by the FDA.
In 1964, a physician in Israel was confronted
with a patient with erythema nodosam leprosum
(ENL), one of the many manifestations of leprosy.
ENL is characterized by painful skin nodules and
nerve damage. With few options, the doctor
administered thalidomide, some of which remained
in a local hospital pharmacy. Within days, the nod-ules vanished and did not return as long as the drug
was continued.
The success of thalidomide as a therapeutic
agent in the treatment of this autoimmune inflam-
matory condition led other investigators to study
thalidomide as a treatment for a number of other
indications thought to have an autoimmune or
inflammatory basis.2 Thalidomide was approved
by the FDA on July 16, 1998 for the treatment of
the cutaneous lesions associated with leprosy. In
addition to controlled clinical trials for treatment
of leprosy and the mucosal lesions of RAU there
are reports of the efficacy of PO thalidomide for
other cutaneous lesions such as pyoderma gangre-
nosum, actinic prurigo, sarcoidosis, and systemic
and discoid lupus, as well as for oral mucosal
lesions of Behcet’s disease and erosive lichen
planus.3–14
The mechanism of action of thalidomide is not
fully understood, and it may be related to immune
modulation, cytokine inhibition, and/or antiangio-
genesis. Importantly the drug is not mutagenic,
cytostatic, or myelosuppressive. The most
frequently cited mechanism is TNF-a inhibition.
Thalidomide reduces TNF-a production by enhanc-
ing the degradation of TNF-a mRNA.2 In addition,
thalidomide produces a variety of effects on the
immune system, including downregulating surface
adhesion molecules and major histocompatibility
antigens on endothelial and epidermal cells, redu-
cing circulating T-helper cells, increasing circulat-
ing T-suppressor cells, and modifying integrin
receptors and other surface receptors.1,3
In vivo data demonstrate antiangiogenic activ-
ity, leading current testing of thalidomide for the
treatment of malignancies.15–18 Antiangiogenic
properties may account for its effect on developing
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implicated as mutagens, cytotoxins, and terato-
gens. Another proposed mechanism of action is
inhibition of integrin activity that relates to inflam-
matory cell recruitment into tissues.19 Thalidomide
has been shown to inhibit neutrophil migration20
and causes neutropenia.21 Similar to its actions on
TNF-a, thalidomide has also been shown to inhibit
IL-12 production,22,23 but also to increase it.24
Viewed together, these basic and clinical re-
search findings suggest a net antiinflammatory
effect of thalidomide via suppression of inflamma-
tory cell trafficking leading to a reduction of pro-
inflammatory cytokines and other inflammatory
mediators. However, Jacobson (1997) report unex-
pected increases in the plasma concentration of
TNF-a and soluble TNF receptors in HIV seropositive
patients treated with PO thalidomide for RAU.
Moreover, HIV viral load increased significantly in
the group receiving PO thalidomide as compared
to the group receiving placebo. Although the mech-
anism for the increase in viral replication was not
assessed in that study, thalidomide has been shown
to enhance T-cell proliferation and IL-2 produc-
tion.25 A pro-inflammatory action of thalidomide
has been reinforced by recent reports of increased
plasma pro-inflammatory cytokine concentrations
in patients being treated with thalidomide. TNF-a
and IL-12 were elevated in scleroderma patients26
and in toxic epidermal necrolysis27 patients being
treated with thalidomide.28,29 In both of these stud-
ies elevation of these plasma cytokine concentra-
tions were accompanied by life-threatening sepsis.
Thalidomide has demonstrated efficacy in HIV-
infected patients with oral aphthous ulcers13 and
idiopathic esophageal ulcers.14 In the oral ulcera-
tion trial, 16 (55%) of 29 patients had complete
healing after four weeks of thalidomide 200 mg
po qhs vs. 2 (7%) of 28 patients in the placebo
group. The thalidomide group also experienced re-
duced oral pain and improved ability to eat. Twelve
patients with idiopathic esophageal ulcers were
treated with thalidomide 200 mg po qhs resulting
in a 92% complete symptomatic response.14 Few
studies have evaluated the use of thalidomide in
AIDS-related Kaposi’s sarcoma (KS). Bower et al.20
reported on 17 men with low-dose thalidomide
(100 mg po qhs) for two months and had encourag-
ing results. Politi and et al.21 treated nine patients
with mucosal KS lesions. Thalidomide was adminis-
tered daily in divided oral doses at four dose levels:
200, 300, 400, and 600 mg. A significant resolution
was seen independent of the dose. Yarchoan and
et al.22 reported on the effect of thalidomide in
11 patients with AIDS-related KS. Thalidomide
was initiated at 200 mg/day and was increased by200 mg/day on a biweekly basis as tolerated to a
maximum dose of 1000 mg/day. Thalidomide ap-
pears to be a promising agent for the treatment
of AIDS-related KS as well.
Thalidomide has been associated with neuropa-
thy (characterized as distal lower extremity painful
paraesthesia, anesthesia and/or delayed motor
weakness, which can be irreversible. The neuropa-
thy results from axonal degeneration without
demyelination in the sensory fibers of the lower
and occasionally upper extremities. Risk of periph-
eral neuropathy appears to rise with patient age
and cumulative dose of thalidomide, resulting in
an incidence of approximately 25% in non-leproma-
tous patients on chronic thalidomide therapy.30
This toxicity initially presents as numbness of toes
and feet then superficial sensory loss in feet and
hands. If therapy is not discontinued, the paresthe-
sias of feet and hands will become permanent and
will progress proximally.31 Universally, sedation or
drowsiness and constipation are known side effects
of thalidomide, regardless of the application of the
drug. Some patients are more sensitive to these
effects than others. Other less common clinical
side effects include allergic vasculitis, brittle
fingernails, decreased libido, dizziness, exfolia-
tive reaction, erythrodermic reaction, face/limb
edema, galactorrhea, increased appetite, menstru-
ation abnormalities, mood changes, nausea, pruri-
tis, red palms, thrombocytopenic purpura, and
xerostomia.
We present an unusual case documenting the use
of thalidomide in the concurrent management of
recurrent aphthous ulceration and kaposi sarcoma
in a patient with severe immmunosuppression.References
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